GLP-1, GIP & glucagon receptor agonists: a research overview
Much of current metabolic-signaling research centers on a small family of receptors and the compounds that activate them. This is a plain-English, mechanism-level overview of how those compounds are classified in the scientific literature — what a single, dual, or triple agonist is, and what distinguishes them.
01The three receptors
Three receptors recur throughout metabolic research. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin receptors, studied for their role in insulin signaling. The glucagon receptor is studied in glucose and energy-balance signaling. These are the signaling pathways a large body of current peptide research is built around.
02Single, dual, and triple agonism
An agonist is a molecule that binds and activates a receptor. Research compounds in this area are classified by how many of the three receptors they act on — a structural and pharmacological distinction that is the main axis of comparison in the literature.
03Why the receptor count matters in research
The reason the single/dual/triple distinction is studied so closely is that acting on more receptors changes the signaling profile a compound produces. Each addition is a separate pharmacological question — how the receptors interact, how selectivity is maintained, how binding at one affects the others. This is what receptor-binding and in-vitro signaling studies exist to characterize, and it is why these compounds are compared class-by-class rather than lumped together.
04Regulatory status is part of the picture
Regulatory standing varies across these compounds and is itself relevant context. Several — including retatrutide — are investigational and not FDA-approved, not available for prescription or purchase as drugs, and not eligible for compounding under current FDA enforcement. They are referenced in research literature and studied in trials; that is a different thing from being an approved therapeutic. Any laboratory research material is supplied for research use only.
05Where analytical quality comes in
All of this depends on knowing precisely what is being studied. Receptor-binding data is only as good as the identity and purity of the material behind it — a truncated or misidentified peptide yields misleading results. That is why per-batch analytical documentation — HPLC for purity, mass spectrometry for identity — is foundational to credible work in this area, and why it is worth understanding how to read that documentation.
Common questions
What is the difference between GLP-1, GIP and glucagon receptors?
They are three distinct receptors in metabolic signaling research. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin receptors involved in insulin signaling; the glucagon receptor is involved in glucose and energy-balance signaling. Research compounds are classified by how many of these receptors they act on.
What is a dual or triple receptor agonist?
An agonist is a molecule that activates a receptor. A single agonist acts on one receptor (e.g. semaglutide at GLP-1); a dual agonist acts on two (tirzepatide at GLP-1 and GIP); a triple agonist acts on three (retatrutide at GLP-1, GIP and glucagon). The distinction is a structural and pharmacological one studied in the literature.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational compound in clinical trials and is not FDA-approved, not available for prescription or purchase as a drug, and not eligible for compounding under current FDA enforcement. It is referenced here only as a subject of published research, not as a product for use.
How are these compounds studied in a laboratory setting?
In research contexts these peptides are examined through receptor-binding assays, in-vitro signaling studies, and preclinical and clinical trials reported in the scientific literature. Laboratory research materials are supplied for research use only and are not for human or veterinary use.
Why does purity matter for receptor research?
Receptor-binding and signaling studies depend on knowing exactly what is in the vial. A truncated or misidentified peptide produces misleading data. That is why analytical documentation — HPLC purity and mass-spectrometry identity confirmation on a per-batch Certificate of Analysis — is fundamental to this kind of research.
Sourcing research compounds is a documentation problem
Whatever the compound, credible research starts with verified material. Learn how to read the analytical documentation, or see what verification looks like done properly.
How to read a COA → Reconstitution calculator →For research use only — not for human or veterinary use. This page is an educational overview of receptor pharmacology as described in the scientific literature. It makes no therapeutic or human-use claims about any compound, is not medical or dosing guidance, and does not offer any named investigational compound for sale or use. Compounds that are not approved by the FDA are not available for purchase as drugs.